摘要
目的:观察血府逐瘀口服液对冠心病血瘀证患者血液流变学的影响,分析其与血小板膜糖蛋白Ⅱb(glycoproteinⅡb,GPⅡb)人类血小板抗原3(human platelet antigen-3,HPA-3)基因多态性的相关性。方法:筛选符合入选标准的32例冠心病血瘀证患者,进行血瘀证计分并检测血液流变学,采用TaqMan探针技术检测GPⅡb HPA-3基因多态性,血府逐瘀口服液治疗4周后复查血液流变学并进行血瘀证计分。结果:血府逐瘀口服液治疗后冠心病血瘀证患者血液流变学得到改善,含有至少一个突变型基因C的患者治疗前后血液黏度、红细胞变形指数及血瘀证计分与AA型患者比较,差异有统计学意义(P<0.05)。结论:血府逐瘀口服液能减轻冠心病血瘀证患者的血瘀症状,改善冠心病血瘀证患者的血液流变性,这种改善作用与GPⅡb HPA-3基因多态表型有相关性。
Objective： To investigate the effects of Xuefu Zhuyu Oral Liquid, a compound traditional Chinese herbal medicine for resolving stagnation, on hemorheology in the patients with blood-stasis syndrome due to coronary disease and their relationship with human platelet antigen-3 （HPA-3） polymorphism of membrane glycoprotein Ⅱb （GP Ⅱ b）. Methods. Thirty-two patients with blood-stasis syndrome due to coronary disease were selected in this study. Blood-stasis syndrome scoring was performed and hemorheological parameters were measured in all subjects before and after Xuefu Zhuyu Qral Liquid treatment. The genotypes of GP Ⅱ b HPA-3 were determined by TaqMan probe technology. Results： The hemorheology was improved in the patients with blood-stasis syndrome due to coronary heart disease after the treatment. There were significant differences in the whole blood viscosity, deformation index of red blood cells and scores of biood-stasis syndrome between the patients carrying AC plus CC and the patients carrying AA after the treatment （P〈0. 05）. Conclusion： Xuefu Zhuyu Oral Liquid can improve clinical symptoms and hemorheology in the patients with blood-stasis syndrome due to coronary heart disease, which is related to GP Ⅱb HPA-3 polymorphism.
出处
《中西医结合学报》
CAS
2008年第11期1129-1135,共7页
Journal of Chinese Integrative Medicine
基金
国家自然科学基金重大研究计划重点项目(No.90409021)
关键词
血府逐瘀口服液
冠心病
血瘀
血液流变学
血小板膜糖蛋白Ⅱb
基因
Xuefu Zhuyu Oral Liquid
coronary heart disease
blood stasis
hemorheology
platelet membrane glycoprotein Ⅱ b
genes
